The immunoglobulin market size was USD 13.36 billion in 2023 and it will hit USD 24.98 billion by 2032, rising at a CAGR of 7.20% by the end of this decade.
Key Takeaways
- North America contributed more than 46% market share in 2022.
- Asia-Pacifica is estimated to witness the fastest CAGR between 2023 and 2032.
- By application, the hypogammaglobulinemia segment has held the largest market share of 38% in 2022.
- By application, the immunodeficiency disease segment is anticipated to grow at a remarkable CAGR of 9.1% between 2023 and 2032.
- By product, the IgA segment generated over 41% of market share in 2022.
- By product, the IgG segment is expected to expand at the fastest CAGR over the projected period.
- By mode of delivery, the Intravenous segment had the largest market share of 66% in 2022.
- By mode of delivery, the subcutaneous segment is expected to expand at the fastest CAGR over the projected period.
The Immunoglobulin market is a dynamic and critical segment within the pharmaceutical and healthcare industry, primarily focusing on the production and distribution of immunoglobulin products. Immunoglobulins, also known as antibodies, play a vital role in the immune system, offering therapeutic applications for various diseases and disorders. The market encompasses a wide range of immunoglobulin products, including intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others, contributing significantly to the global healthcare landscape.
Region Snapshot
The Immunoglobulin market exhibits a global presence, with key regions including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America and Europe often lead in terms of market share, driven by advanced healthcare infrastructure, high awareness levels, and robust research and development activities. Meanwhile, the Asia-Pacific region demonstrates rapid growth, attributed to increasing healthcare expenditure, rising prevalence of immunodeficiency disorders, and improving accessibility to healthcare services.
Get a Sample: https://www.precedenceresearch.com/sample/3646
Growth Factors:
The market’s growth is propelled by factors such as the rising incidence of immunodeficiency disorders, expanding geriatric population, and advancements in biotechnological processes for immunoglobulin production. Additionally, the increasing awareness about immunoglobulin therapies and their effectiveness in treating various autoimmune and infectious diseases contributes significantly to market expansion.
Immunoglobulin Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 7.20% |
| Market Size in 2023 | USD 13.36 Billion |
| Market Size by 2032 | USD 24.98 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Application, By Product, and By Mode of Delivery |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers:
Key drivers influencing the Immunoglobulin market include the growing prevalence of autoimmune diseases, advancements in plasma fractionation techniques, and the expanding application of immunoglobulin in neurological disorders. The market is further driven by the surge in research and development activities, leading to the introduction of novel immunoglobulin products with improved efficacy and reduced side effects.
Opportunities:
Opportunities in the Immunoglobulin market lie in the untapped potential of emerging markets, where a growing patient population and increasing healthcare infrastructure create a favorable environment for market expansion. Moreover, ongoing research exploring new therapeutic applications for immunoglobulins presents avenues for product diversification and extended market reach.
Challenges:
Despite its promising outlook, the Immunoglobulin market faces challenges such as regulatory hurdles, the high cost of immunoglobulin therapies, and the potential for adverse effects. Ensuring a stable and sustainable supply of plasma, a primary raw material for immunoglobulin production, poses another challenge, emphasizing the need for effective supply chain management.
Competition Landscape:
The Immunoglobulin market is characterized by intense competition among key players, including pharmaceutical companies, biotechnology firms, and plasma product manufacturers. Leading companies engage in strategic initiatives such as mergers and acquisitions, partnerships, and product innovations to strengthen their market position. The competitive landscape is also influenced by factors such as pricing strategies, distribution networks, and the ability to meet the growing demand for immunoglobulin products globally.
Read Also: Genitourinary Drugs Market Size to Touch US$ 32.27 Bn By 2032
Recent Developments
- In 2023, Everest Medicines gained approval from the Hainan Medical Products Administration for clinical use of Nefecon, a primary immunoglobulin A nephropathy (IgAN) drug, in China. This milestone marks progress in addressing IgAN, a condition affecting the kidneys, enhancing treatment options for patients in the region.
- In 2022, Grifols secured approval from European Union member state health authorities and the United Kingdom for XEMBIFY, a groundbreaking 20% subcutaneous immunoglobulin (SCIG). This innovative treatment is authorized for addressing primary and specific secondary immunodeficiency, marking a significant advancement in therapeutic options for these conditions.
- In 2021, Octapharma USA’s investigational new drug (IND) application for a phase three clinical trial assessing the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in severe COVID-19 patients received authorization from the U.S. Food and Drug Administration (FDA).
Immunoglobulin Market Players
- Grifols, S.A.
- Shire
- CSL Behring
- Kedrion S.p.A.
- Octapharma
- Baxter International Inc.
- Biotest AG
- Bio Products Laboratory Ltd. (BPL)
- China Biologic Products Holdings, Inc.
- LFB SA
- Cangene Corporation
- Bharat Serums and Vaccines Limited
- Takeda Pharmaceutical Company Limited
- Bio Products Laboratory Ltd. (BPL)
- China National Pharmaceutical Group Corporation (Sinopharm)
Segments Covered in the Report
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory Demyelinating Polyneuropathy
- Immunodeficiency Disease
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillainâ€Barré Syndrome
- Others
By Product
- IgA
- IgG
- IgM
- IgE
- IgD
By Mode of Delivery
- Intravenous
- Subcutaneous
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
